Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccination by Tscherne, Alina, Schwarz, Jan Hendrik, Rohde, Cornelius, Kupke, Alexandra, Kalodimou, Georgia, Limpinsel, Leonard, Nisreen Ma Okba, Bošnjak, Berislav, Sandrock, Inga, Halwe, Sandro, Sauerhering, Lucie, Brosinski, Katrin, Liangliang, Nan, Duell, Elke, Jany, Sylvia, Freudenstein, Astrid, Schmidt, Jörg, Werner, Anke, Michelle Gellhorn Sera, Klüver, Michael, Guggemos, Wolfgang, Seilmaier, Michael, Clemens-Martin Wendtner, ster, Reinhold, Haagmans, Bart L, Becker, Stephan, Sutter, Gerd, Volz, Asisa

Request full text